Shares of Elevance Health Inc. ELV slipped 1.42% to $405.40 Tuesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 0.92% to 6,067.70 and the Dow Jones Industrial Average DJIA rising 0.31% to 44,850.35.

We took advantage of Elevance Health's share price weakness in the fourth quarter and added modestly to our investment. Click here to read more.

Elevance Health Inc. closed 27.50% below its 52-week high of $567.26, which the company achieved on September 3rd.

Financial writer recommends buying Elevance Health stock despite recent drop, citing strong industry trends and potential for significant upside.

NEW YORK: The benchmark S&P 500 rose to a record closing high ... it forecast 2025 profit above estimates and shares in health insurer Elevance rose 2.7% after beating estimates for fourth-quarter ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Elevance Health delivered earnings and 2025 guidance that broadly met analysts’ expectations, likely providing some relief to investors after a challenging quarter. The fourth-quarter results ...

U.S. stocks rose to a record as Wall Street regained some of the momentum that catapulted it to 57 all-time highs last year.

Elevance Health Inc.'s stock rose 2% Thursday ... The stock has fallen 16% in the last 12 months, while the S&P 500 SPX has gained 25%. Chip stocks and other AI-related plays take a hit as ...

Analysts' ratings for Elevance Health ELV over the last quarter vary from bullish to bearish, as provided by 6 analysts. Summarizing their recent assessments, the table below illustrates the ...

As you can see from the chart above the percentage of shares that are sold short for Elevance Health has grown since its last report. This does not mean that the stock is going to fall in the near ...

TD Cowen analyst Ryan Langston has maintained their bullish stance on ELV stock, giving a Buy rating on January 24. Ryan Langston has given his Buy rating due to a combination of factors ...